Vertex Pharmaceuticals (VRTX) Upgraded to Buy by Maxim Group | V

2026-03-26 06:25:04

Abstract generation in progress

Maxim Group analyst Naz Rahman upgraded Vertex Pharmaceuticals (VRTX) from a “Hold” to a “Buy” rating, setting a new price target of $575.00. This upgrade aligns with a series of bullish actions from other analysts in March 2026, including raised price targets and an “Outperform” consensus from 34 brokerage firms. Wall Street analysts forecast an average target price of $544.76 for VRTX, implying a 20.34% upside from its current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.